The Supreme Court’s ruling in Riegel v. Medtronic, Inc., may prevent consumers injured by medical devices that have FDA premarket approval from receiving compensation.
Medicine, a high-energy consumer and generator of much waste—some of it toxic—must scale back the health care enterprise in the interest of preserving a livable environment.
There is a market for direct-to-consumer genetic testing and a need for better consumer information and more regulation of tests and testing laboratories.